Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis

Lupus

Volumn 23, Issue 8, 2014, Pages 813-818

  Tanaka, H ^a,b   Aizawa, T ^a   Watanabe, S ^a   Oki, E ^a   Tsuruga, K ^a   Imaizumi, T ^c  

^a HIROSAKI UNIVERSITY HOSPITAL   (Japan)

^b HIROSAKI UNIVERSITY   (Japan)

^c HIROSAKI UNIVERSITY   (Japan)

Author keywords

Lupus nephritis; Mizoribine; Multitarget therapy; Pediatric onset; Systemic lupus erythematosus; Tacrolimus

Indexed keywords

COMPLEMENT COMPONENT C3; CREATININE; DOUBLE STRANDED DNA ANTIBODY; GLYCOSYLATED HEMOGLOBIN; METHYLPREDNISOLONE; MIZORIBINE; PREDNISOLONE; RITUXIMAB; TACROLIMUS; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; RIBONUCLEOSIDE;

ADOLESCENT; AMENORRHEA; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; EVENING DOSAGE; FEMALE; GASTROINTESTINAL SYMPTOM; HEMATURIA; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERGLYCEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LEUKOPENIA; LIVER DYSFUNCTION; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; ONSET AGE; PEDIATRIC LUPUS NEPHRITIS; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN URINE LEVEL; SIDE EFFECT; TREATMENT DURATION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; INDUCTION CHEMOTHERAPY; LUPUS NEPHRITIS; TREATMENT OUTCOME;

ADOLESCENT; CHILD; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INDUCTION CHEMOTHERAPY; LUPUS NEPHRITIS; MALE; PILOT PROJECTS; PREDNISOLONE; PROSPECTIVE STUDIES; RIBONUCLEOSIDES; TACROLIMUS; TREATMENT OUTCOME;

EID: 84903530961     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314528553     Document Type: Article

References (22)

1. Lai KN, Tang SCW, Mok CC. Treatment for lupus nephritis: A revisit. Nephrology (Carlton) 2005; 10: 180-188.
2. Tanaka H, Oki E, Tsuruga K, et al. Mizoribine treatment of young patients with severe lupus nephritis: A clinicopathologic study by the Tohoku Pediatric Study Group. Nephron Clin Pract 2008; 110: c73-c79.
3. Tanaka H, Tsuruga K, Watanabe S, Aizawa-Yashiro T, Imaizumi T. Treatment of young patients with lupus nephritis using calcineurin inhibitors. W J Nephrol 2012; 1: 177-183.
4. Lehman TJ, Onel K. Intermittent intravenous cyclophosphamide arrests progression of the renal chronicity index in childhood systemic lupus erythematosus. J Pediatr 2000; 136: 243-247.
5. Lee T, Oh KH, Joo KW, et al. Tacrolimus is an alternative therapeutic option for the treatment of refractory lupus nephritis. Lupus 2010; 19: 974-980.
6. Chen W, Tang X, Liu Q, et al. Short-term outcomes of induction therapy with tacrolimus versus cyclophosphamide for active lupus nephritis: A multicenter randomized clinical trial. Am J Kidney Dis 2011; 57: 235-244.
7. Chen W, Liu Q, Chen W, et al. Outcomes of maintenance therapy with tacrolimus versus azathioprine for active lupus nephritis: A multicenter randomized clinical trial. Lupus 2012; 21: 944-952.
8. Asamiya Y, Uchida K, Otsubo S, Takei T, Nitta K. Clinical assessment of tacrolimus therapy in lupus nephritis: One-year follow-up study in a single center. Nephron Clin Pract 2009; 113: c330-c336.
9. Takahashi S, Hiromura K, Sakurai N, et al. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis. Mod Rheumatol 2011; 21: 282-289.
10. Aragon E, Chan YH, Ng KH, Lau YW, Tan PH, Yap NK. Good outcome with mycophenolate-cyclosporine-based induction protocol in children with severe proliferative lupus nephritis. Lupus 2010; 19: 965-973.
11. Tanaka H, Watanabe S, Aizawa-Yashiro T, et al. Long-term tacrolimus- based immunosuppressive treatment for young patients with lupus nephritis: A prospective study in daily clinical practice. Nephron Clin Pract 2012; 121: c165-c173.
12. Bao H, Liu ZH, Xie HL, Hu WX, Zhang HT, Li LS. Successful treatment of class V+IV lupus nephritis with multitarget therapy. J Am Soc Nephrol 2008; 19: 2001-2010.
13. Lanata CM, Mahmood T, Fine DM, Petri M. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis. Lupus 2010; 19: 935-940.
14. Cortés-Hernández J, Torres-Salido MT, Medrano AS, Tarrés MV, Ordi-Ros J. Long-term outcomes - mycophenolate mofetil treatment for lupus nephritis with addition of tacrolimus for resistant cases. Nephrol Dial Transplant 2010; 25: 3939-3948.
15. Kawasaki Y. Mizoribine: New approach in the treatment of renal disease. Clin Dev Immunol 2009; 2009: 681482.
16. Aizawa-Yashiro T, Tsuruga K, Watanabe S, et al. Long-term multidrug therapy in an adolescent patient with proliferative lupus nephritis: A trail of less cytotoxic therapy. Clin Nephrol 2012; 78: 332-334.
17. Kagawa H, Hiromasa T, Hara T, et al.Mizoribine, tacrolimus, and corticosteroid combination therapy successfully induces remission in patients with lupus nephritis. Clin Exp Nephrol 2012; 16: 760-766.
18. Nomura A, Shimizu H, Kishimoto M, et al. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus 2012; 21: 1444-1449.
19. Hara S, Umino D, Someya T, et al. Protective effects of mizoribine on cyclosporine A nephropathy in rats. Pediatr Res 2009; 66: 524-527.
20. Tanaka H, Oki E, Tsuruga K, et al. Mizoribine attenuates renal injury and macrophage infiltration in patients with severe lupus nephritis. Clin Rheumatol 2010; 29: 1049-1054.
21. Aizawa-Yashiro T, Tsuruga K, Watanabe S, Oki E, Ito E, Tanaka H. Novel multidrug therapy for children with cyclosporine-resistant or -intolerant nephrotic syndrome. Pediatr Nephrol 2011; 26: 1255-1261.
22. Tsujimura S, Tanaka Y. Treatment strategy based on targeting P-glycoprotein on peripheral lymphocytes in patients with systemic autoimmune disease. Clin Exp Nephrol 2012; 16: 102-108.